Plaintiffs plan to appeal a decision granting summary judgment to Eli Lilly, Merck and other makers of four diabetes drugs on claims the companies should have warned about the risk of pancreatic cancer, one of their attorneys says (In re Incretin-Based Therapies Prod. Liab. Litig., S.D. Cal., 13-2452, 11/9/15).

Federal law preempts the failure-to-warn claims because the FDA would have rejected the warnings the plaintiffs sought, Judge Anthony J. Battaglia of the U.S. District Court for the...